ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck and Moderna side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MerckModerna
studies on the registry2,453119
open to participants now14518
phase 3 studies under way1122
reach primary completion within a year6016
programswith a study of their own in two years8516

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerckModerna
Phase 1

Merck: 27 of its 85 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%

Moderna: 5 of its 16 programs at phase 1

  1. MRNA-1365phase 1
  2. MRNA-1469phase 1
  3. mRNA-1519phase 1
  4. MRNA-4106phase 1
  5. MRNA-4200phase 1
31%
Phase 222%31%
Phase 3

Merck: 36 of its 85 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 31 more — sign in to see them all

42%

Moderna: 3 of its 16 programs at phase 3

  1. mRNA-1345 respiratory syncytial virus vaccinephase 3
  2. MRNA-1018phase 3
  3. MRNA-1083phase 3
19%
Approved, new studies

Merck: 3 of its 85 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Moderna: 3 of its 16 programs at approved, new studies

  1. 2019-nCoV Vaccine mRNA-1273approved, new study
  2. MRNA-1283approved, new study
  3. mRNA-1010 influenza vaccineapproved, new study
19%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
Moderna9 readouts · 4 phase 3·

Moderna, Dec ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. mRNA-1010 influenza vaccineapproved, new study · Dec 7 · NCT07884175
  2. 2019-nCoV Vaccine mRNA-1273approved, new study · Dec 11 · NCT07863635
  3. MRNA-1283approved, new study · Dec 11 · NCT07863635

Moderna, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MRNA-1018phase 3 · Jan 28 · NCT07496450
···

Moderna, May ’27: 1 program whose next study reaches primary completion

  1. Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189phase 2 · May 15 · NCT07478952
·

Moderna, Jul ’27: 1 program whose next study reaches primary completion

  1. MRNA-1365phase 1 · Jul 20 · NCT07764237

Moderna, Aug ’27: 2 programs whose next study reaches primary completion

  1. MRNA-4106phase 1 · Aug 3 · NCT06880549
  2. MRNA-4200phase 1 · Aug 3 · NCT06880549

Moderna, Sep ’27: 1 program whose next study reaches primary completion

  1. MRNA-1469phase 1 · Sep 30 · NCT07737717
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Moderna

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionMerckModerna
Influenza, Humanboth · compare here

Merck in Influenza, Human: 1 program

  1. efitazanamivir alfaphase 3

Their studies: Merck’s studies of Influenza, Human in search

Coronavirus Infectionsboth · compare here

Merck in Coronavirus Infections: 1 program

  1. molnupiravirphase 3

Their studies: Merck’s studies of Coronavirus Infections in search

Moderna in Coronavirus Infections: 4 programs

  1. mRNA-1345 respiratory syncytial virus vaccinephase 3
  2. 2019-nCoV Vaccine mRNA-1273approved, new study
  3. MRNA-1283approved, new study
  4. mRNA-1010 influenza vaccineapproved, new study

Their studies: Moderna’s studies of Coronavirus Infections in search

COVID-19both · compare here

Merck in COVID-19: 2 programs

  1. molnupiravirphase 3
  2. frespaciguatphase 3

Their studies: Merck’s studies of COVID-19 in search

Moderna in COVID-19: 3 programs

  1. MRNA-1083phase 3
  2. 2019-nCoV Vaccine mRNA-1273approved, new study
  3. MRNA-1283approved, new study

Their studies: Moderna’s studies of COVID-19 in search

Neoplasm Metastasisboth · compare here

Merck in Neoplasm Metastasis: 1 program

  1. MK-8294phase 1

Their studies: Merck’s studies of Neoplasm Metastasis in search

Moderna in Neoplasm Metastasis: 2 programs

  1. MRNA-4106phase 1
  2. MRNA-4200phase 1

Their studies: Moderna’s studies of Neoplasm Metastasis in search

Multiple Myelomaboth · compare here

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Moderna in Multiple Myeloma: 1 program

  1. mRNA-based T-cell Engager mRNA-2808phase 2

Their studies: Moderna’s studies of Multiple Myeloma in search

Papillomavirus Infectionsboth · compare here

Moderna in Papillomavirus Infections: 1 program

  1. 2019-nCoV Vaccine mRNA-1273approved, new study

Their studies: Moderna’s studies of Papillomavirus Infections in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Merck 41 of 85 · Moderna 5 of 16 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.